Companies › Janux Therapeutics
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JANX007 PSMA-targeting bispecific antibody | – | Phase 1 | Prostate Cancer | Jul 2027 |
| JANX014 Bispecific antibody targeting PSMA and 4-1BB | – | Phase 1 | Prostate Cancer | May 2028 |
| JANX013 | – | Phase 1 | Prostate Cancer | Jul 2029 |
| JANX008 EGFR-targeting therapy | EGFR | Phase 1 | Non-Small Cell Lung Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05783622 | JANX008 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jul 2026 |
| NCT05519449 | JANX007 | Phase 1 | Prostate Cancer | Oncology | Jul 2027 |
| NCT07545811 | JANX014 | Phase 1 | Prostate Cancer | Oncology | May 2028 |
| NCT07813637 | JANX013 | Phase 1 | Prostate Cancer | Oncology | Jul 2029 |
| NCT07813637 | JANX007 | Phase 1 | Prostate Cancer | Oncology | Jul 2029 |
Cash and short-term investments of $946m on 2026-09-30; operating cash outflow about $34m a year; runway about 338 months at that burn, to Nov 2054
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.